Eris Lifesciences Limited — PPTs, 25-10-2024: Investor Presentation

Eris Lifesciences reported robust growth in its Q2 FY25 performance, with consolidated operating revenue rising 47% to INR 741 crore and EBITDA increasing 46% to INR 265 crore. The company maintains its FY25 guidance of INR 2,600 crore for Domestic Branded Formulations with a 36% EBITDA margin. Key developments include successful manufacturing ramp-ups, new product launches, and significant improvements in operating cash flow and return on capital employed. Overall, it reaffirms its strategic direction and growth potential.